(BUSINESS WIRE)--MabSpace Biosciences announced that on August 24th, 2018, MSB2311 was successfully administered to the first Chinese cancer patient at Beijing Cancer Hospital in its China Phase 1 trial.

To Accelerate Biotherapeutics Analysis and Development in China by Bringing in ZipChip Platform
Dedicated to developing global antibody and recombinant protein biotherapeutics, HJB today announced a joint innovation partnership with 908 Devices, a pioneer of purpose-built analytical devices for chemical and biomolecular analysis.

(BUSINESS WIRE)--MabSpace Biosciences announced today that the first subject has been dosed in a Phase 1 clinical study of MSB2311, for the treatment of advanced solid tumors.

HJB, an organization dedicated to expanding global access to important protein therapeutics, recently announced the establishment of its Center of Clinical Development (“the Center”) based in Boston.

(BUSINESS WIRE)--MabSpace Biosciences announces on February 16th, 2018 FDA cleared Investigational New Drug (IND) for MSB2311, a humanized programmed death protein-ligand 1 (PD-L1) antibody for the treatment of patients with locally advanced/metastatic solid tumors.

To benefit global patients by accelerating the design and manufacturing of innovative biologics that meet global standards.
HJB, an organization dedicated to expanding global access to important protein therapeutics, today held the grand opening ceremony for its R&D Center and Manufacturing Facility.